Pharmaceutical Optimization, Molecular Regenerative Mechanisms, and Preclinical Validation of a Topical Mist Formulation Comprising Aloe vera and Centella asiatica Derived Phyto PDRN with Dexpanthenol for Canine and Feline Epidermal Barrier Restorati

To fundamentally resolve the inherent limitations of conventional marine fish (salmon and trout)-derived polydeoxyribonucleotide (PDRN)—specifically residual animal protein allergenicity, intense fishy odor leading to behavioral aversion upon oral licking or topical application in companion animals (aversion rate: 47.5%), and marine heavy metal bioaccumulation risks—this study investigated the pharmaceutical optimization, cellular molecular mechanisms, and preclinical efficacy and safety of a topical mist formulation specifically designed for companion animals (canine and feline). The formulation combines highly purified Phyto-PDRN derived from Aloe vera adventitious roots and Centella asiatica (Cica-PDRN; Sodium DNA, 50–1,500 bp) with dexpanthenol (1.0–1.5%), a pivotal epidermal barrier-repair agent, classified as an animal quasi-drug external topical liquid. Unlike human skin, companion animals possess a fragile stratum corneum composed of merely 3–5 cell layers and maintain a neutral to weakly alkaline epidermal surface pH (canine pH 6.2–7.5; feline pH 6.0–7.2). Accordingly, the final formulation was precisely buffered to pH 6.8–7.2. In an oil-free, water-based aerosol system, the severe nozzle-clogging issue associated with poorly soluble ceramide NP (0.05%) was completely resolved via a liquid nano-solubilization premix technology. Regarding antimicrobial preservation, six harmful synthetic preservatives (including parabens and phenoxyethanol) were entirely excluded; instead, an EWG Grade 1 natural multi-preservative booster system consisting of 1,2-hexanediol (1.0%), sodium phytate (0.05%), and ethylhexylglycerin (0.05%) was established, satisfying USP <51> antimicrobial effectiveness criteria and validating a 24-month shelf-life stability (via 6-month accelerated testing at 40°C/75% RH). In vitro bioactivity evaluations demonstrated that the Aloe and Centella PDRN complex exhibited an outstanding DPPH free radical scavenging activity of 96.0%. In human epidermal keratinocytes (HaCaT) and dermal fibroblasts (HDF), the complex markedly upregulated the gene expressions of antioxidant enzyme SOD1 (135.2%), epidermal barrier structural proteins filaggrin (FLG, 128.4%) and loricrin (LOR, 132.8%), and type I collagen (COL1A1, 142.1%), while potently suppressing matrix metalloproteinase-1 (MMP-1) expression to 48.3%. In particular, selective purinergic adenosine A2A receptor (A2AR) activation accelerated fibroblast proliferation by 215.4% (which was abrogated to 112.1% by the selective A2AR antagonist ZM241385, verifying the specific molecular mechanism) and promoted 94.8% scratch wound closure within 24 h. In cellular and animal preclinical models, the formulation protected feline renal epithelial cells (CRFK) against severe oxidative cytopathy, restoring cell viability to 94.1% and decreasing TUNEL-positive apoptotic cells to 8.2%. In BALB/c mice with full-thickness cutaneous excision wounds, the mist complex induced 96.8% re-epithelialization on day 14 alongside robust neo-capillary CD31 angiogenesis and dense collagen remodeling. Moreover, the formulation demonstrated zero mucosal ocular irritation in the chorioallantoic membrane (HET-CAM score 0.0) and achieved exceptional palatability and acceptance rates (90.0–93.3%) in dogs and cats. Consequently, this study successfully establishes the scientific foundation for an oral-safe, 100% vegan animal quasi-drug mist formulation and validates its commercialization and contract development and manufacturing organization (CDMO) viability.

Authors

Institutions

Publication Details

Journal
International Journal of Current Science Research and Review
Published
2026-11-17
DOI
https://doi.org/10.47191/ijcsrr/v9-i11-26
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmaceutical Optimization, Molecular Regenerative Mechanisms, and Preclinical Validation of a Topical Mist Formulation Comprising Aloe vera and Centella asiatica Derived Phyto PDRN with Dexpanthenol for Canine and Feline Epidermal Barrier Restorati

Jiyeon Kim, Young-Ho Choi, Yeon-Mae Choi, Jun-Gu Lee et al.
International Journal of Current Science Research and Review
Advancements in Transdermal Drug Delivery
article

Pharmaceutical Optimization, Molecular Regenerative Mechanisms, and Preclinical Validation of a Topical Mist Formulation Comprising Aloe vera and Centella asiatica Derived Phyto PDRN with Dexpanthenol for Canine and Feline Epidermal Barrier Restorati

Jiyeon Kim, Young-Ho Choi, Yeon-Mae Choi, Jun-Gu Lee, Dong-Myeong Kim, Sae-Rom Park, Won-Kyu Lee
article en

Abstract

To fundamentally resolve the inherent limitations of conventional marine fish (salmon and trout)-derived polydeoxyribonucleotide (PDRN)—specifically residual animal protein allergenicity, intense fishy odor leading to behavioral aversion upon oral licking or topical application in companion animals (aversion rate: 47.5%), and marine heavy metal bioaccumulation risks—this study investigated the pharmaceutical optimization, cellular molecular mechanisms, and preclinical efficacy and safety of a topical mist formulation specifically designed for companion animals (canine and feline). The formulation combines highly purified Phyto-PDRN derived from Aloe vera adventitious roots and Centella asiatica (Cica-PDRN; Sodium DNA, 50–1,500 bp) with dexpanthenol (1.0–1.5%), a pivotal epidermal barrier-repair agent, classified as an animal quasi-drug external topical liquid. Unlike human skin, companion animals possess a fragile stratum corneum composed of merely 3–5 cell layers and maintain a neutral to weakly alkaline epidermal surface pH (canine pH 6.2–7.5; feline pH 6.0–7.2). Accordingly, the final formulation was precisely buffered to pH 6.8–7.2. In an oil-free, water-based aerosol system, the severe nozzle-clogging issue associated with poorly soluble ceramide NP (0.05%) was completely resolved via a liquid nano-solubilization premix technology. Regarding antimicrobial preservation, six harmful synthetic preservatives (including parabens and phenoxyethanol) were entirely excluded; instead, an EWG Grade 1 natural multi-preservative booster system consisting of 1,2-hexanediol (1.0%), sodium phytate (0.05%), and ethylhexylglycerin (0.05%) was established, satisfying USP <51> antimicrobial effectiveness criteria and validating a 24-month shelf-life stability (via 6-month accelerated testing at 40°C/75% RH). In vitro bioactivity evaluations demonstrated that the Aloe and Centella PDRN complex exhibited an outstanding DPPH free radical scavenging activity of 96.0%. In human epidermal keratinocytes (HaCaT) and dermal fibroblasts (HDF), the complex markedly upregulated the gene expressions of antioxidant enzyme SOD1 (135.2%), epidermal barrier structural proteins filaggrin (FLG, 128.4%) and loricrin (LOR, 132.8%), and type I collagen (COL1A1, 142.1%), while potently suppressing matrix metalloproteinase-1 (MMP-1) expression to 48.3%. In particular, selective purinergic adenosine A2A receptor (A2AR) activation accelerated fibroblast proliferation by 215.4% (which was abrogated to 112.1% by the selective A2AR antagonist ZM241385, verifying the specific molecular mechanism) and promoted 94.8% scratch wound closure within 24 h. In cellular and animal preclinical models, the formulation protected feline renal epithelial cells (CRFK) against severe oxidative cytopathy, restoring cell viability to 94.1% and decreasing TUNEL-positive apoptotic cells to 8.2%. In BALB/c mice with full-thickness cutaneous excision wounds, the mist complex induced 96.8% re-epithelialization on day 14 alongside robust neo-capillary CD31 angiogenesis and dense collagen remodeling. Moreover, the formulation demonstrated zero mucosal ocular irritation in the chorioallantoic membrane (HET-CAM score 0.0) and achieved exceptional palatability and acceptance rates (90.0–93.3%) in dogs and cats. Consequently, this study successfully establishes the scientific foundation for an oral-safe, 100% vegan animal quasi-drug mist formulation and validates its commercialization and contract development and manufacturing organization (CDMO) viability.

International Journal of Current Science Research and ReviewVol. 09(11)
Seoul National University (KR), National Research Foundation of Korea (KR)
Advancements in Transdermal Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon